RIPCORDS FIBERS PROCESSES PRODUCTS MOVING HIGH PERFORMANCE FIBERS FORWARD This data is provided for informational purposes only, and does not constitute a specification. Uranusweg 3 8938 AJ Leeuwarden The Netherlands +31(0) 58 216 75 99 info@fiber-line.com ABOUT FIBER-LINE® NOTICE: The information and data contained herein do not constitute sales specifications.

INDUSTRIAL FABRIC YARN FIBERS PROCESSES PRODUCTS MOVING HIGH PERFORMANCE FIBERS FORWARD This data is provided for informational purposes only, and does not constitute a specification. Uranusweg 3 8938 AJ Leeuwarden The Netherlands +31(0) 58 216 75 99 info@fiber-line.com NOTICE: The information and data contained herein do not constitute sales specifications.

MOVING HIGH PERFORMANCE FIBERS FORWARD This data is provided for informational purposes only, and does not constitute a specification. Uranusweg 3 8938 AJ Leeuwarden The Netherlands +31(0) 58 216 75 99 info@fiber-line.com NOTICE: The information and data contained herein do not constitute sales specifications.

TECHNICAL PROPERTIES(1) TEST METHOD Complēt LGF30-PKE NAT Complēt LGF40-PKE NAT Complēt LGF50-PKE NAT Physical Density/Specific Gravity ASTM D792 1.47 1.54 1.66 Mechanical Tensile Strength (Yield) ASTM D638 21,100 psi 24,700 psi 26,400 psi Tensile Modulus(2) ASTM D638 1,150,000 psi 1,570,000 psi 2,150,000 psi Flexural Modulus(3) ASTM D790 1,120,000 psi 1,480,000 psi 2,030,000 psi Flammability (non-PFAS options available) Flame Rating @ 1.5 mm UL 94 V-0 V-0 — COLD IMPACT PERFORMANCE Ft -lb /in Data based on single lot of lab-generated samples. Values are not to be construed as specifications. ■ Notched 23C ■ Unnotched 23C ■ Unnotched -30C■ Notched -30C 0 5 10 15 20 25 Complēt LGF30-PKE NAT Complēt LGF40-PKE NAT Complēt LGF50-PKE NAT Izod Impact Notched ASTM D256/Unnotched ASTM D4812 4.1 4.7 5.4 18.9 19.5 19.919.1 19.8 20.1 4.0 4.6 5.0 (1) Data based on single lot of lab generated samples.

We are Avient. 4 BETTER TOGETHER: POLYONE AND CLARIANT MASTERBATCH Key Data 2021E Sales $4.1 billion 2021E EBITDA $510 million 2021E Free Cash Flow $250 million 87% of EBITDA from specialty applications Innovation is the lifeblood of a specialty company. D is t. ) R P M P P G K W R F U L A V Y G C P IF F F M C H X L H U N E M N F O E E C L K R A S C L A S H C E G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of February 5, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of February 5, 2021 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi en t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of February 5, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets.

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 43 Capex / Revenue 2022E (%) AVIENT IS ASSET LIGHT Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 2 3 4 3 3 5 5 7 7 8 11 Av ie nt Av ie nt P F FU L KW R PP G R PM AV Y FM C H U N H XL EC L EM N C E AS H SC L Source: Peer data per Bloomberg market data as of April 21, 2022. Source: Peer data per Bloomberg market data as of April 21, 2022 86 82 86 86 84 78 77 89 86 81 80 76 76 76 67 67 11 (12) Av ie nt Av ie nt P F FU L KW R PP G R PM AV Y FM C U N VR BN R H U N H XL EC L C E AS H EM N SC L AL B 12% 18% 16% 15% 15% 14% 14% 28% 28% 26% 25% 22% 21% 19% 16% 12% 9% 9% Av ie nt T od ay Av ie nt P F AV Y PP G KW R FU L R PM C E AL B FM C AS H EC L EM N H XL H U N SC L BN R U N VR Median: 21%Median: 15% 2022 EBITDA MARGINS VS. Financials are pro forma for the acquisition of Dyneema® and potential divestiture of Distribution Avient Specialty Formulators Other Specialty / Chemical Companies 45 Source: Peer data per Bloomberg market data as of April 21, 2022 Total Enterprise Value / NTM EBITDA With the Dyneema and Clariant Color business acquisition and divestment of the PP&S business, along with the proposed sale of our Distribution business, our exposure is now concentrated in less-cyclical and high-growth markets.

We are Avient. 4 BETTER TOGETHER: POLYONE AND CLARIANT MASTERBATCH Key Data 2020 PF Sales (1) $3.7 billion 2020 PF EBITDA (1) $425 million ($500M w/synergies) Free Cash Flow $240 million (1) Estimated Pro forma for the acquisition of the Clariant Masterbatch business 87% of EBITDA from specialty applications U.S. & Canada 49% Europe 25% Asia 17% Latin America 9% SEGMENT, END MARKET AND GEOGRAPHY 5 GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 23% Packaging 21%Industrial 15% Wire & Cable 7% Building & Construction 6% Electrical & Electronics 4% END MARKET REVENUE Transportation 9% Healthcare 15% All data reflects 2020 estimate and Pro forma for acquisition of the Clariant Masterbatch business. (1) The total company sales and EBITDA of $3,650M and $425M, respectively, include intercompany sales eliminations and corporate costs $2,000M $310M $685M $115M $1,050M $65M Sales EBITDA Distribution Specialty Engineered Materials Color Additives and Inks $425M$3,650M (1) Innovation is the lifeblood of a specialty company. It’s why we win. 11 474 644 924 107 147 208 467 616 872 2014 2018 2020PF R&D / Technical Marketing Sales Commercial Resources + 36% + 37% + 32% + 43% + 41% + 42% Headcount figures are Pro forma for the sale of Designed Structures and Solutions (DSS) and Performance Products and Solutions (PP&S) segments and the acquisition of the Clariant Masterbatch business. 2020PF data as of August 31, 2020. Consensus EBITDA of $460M per Bloomberg Source: Capital IQ market data as of August 24, 2020 Median: 14.1x Median: 10.1x OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies SUMMARY: WHY INVEST IN AVIENT?

D is t. ) R P M P P G K W R F U L A V Y G C P IF F F M C H X L H U N E M N F O E E C L K R A S C L A S H C E G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of February 5, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of February 5, 2021 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi en t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of February 5, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets. Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.

It’s why we win. 11 474 644 925 107 147 212 467 616 858 2014 2018 2020PF R&D / Technical Marketing Sales Commercial Resources + 36% + 37% + 32% + 44% + 44% + 39% Headcount figures are Pro forma for the sale of Designed Structures and Solutions (DSS) and Performance Products and Solutions (PP&S) segments and the acquisition of the Clariant Masterbatch business. 2020PF data as of October 31, 2020. Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 17 Capex / Revenue 2021E (%) Source: Bloomberg market data as of November 9, 2020 AVIENT IS ASSET LIGHT Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 3 3 3 6 3 4 5 5 5 5 5 6 6 7 7 9 24 A v ie n t A v ie n t (E x c l. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Source: Bloomberg market data as of November 9, 2020 Median: 82% Median: 73% HIGH FREE CASH FLOW CONVERSION 83 86 85 85 80 78 58 88 83 81 79 77 76 73 73 72 72 67 64 63 60 6 A v ie n t K W R R P M P P G F U L A V Y G C P F M C IF F U N V R B N R E M N E C L C E H X L F O E A S H G R A H U N K R A S C L A L B Net Debt / 2021E EBITDA (1) We typically operate at 2.5–3.0x net debt to EBITDA.

Continue fostering our Great Place to Work® culture Strategic ObjectivesStrategic Objectives Long Term Growth Rates Growth DriversGrowth Drivers $340 $455 $790 $1,175 2016 2018 2020 2022 $51 $84 $212 $668 2016 2018 2020 2022 $108 $113 $231 $293 2016 2018 2020 2022 $265 $358 $726 $830 2016 2018 2020 2022 8-12% 10% 8-10% 5% Sustainable Solutions Composites Healthcare Asia/Emerging Regions Profitable GrowthProfitable Growth Great Place to WorkGreat Place to Work 5.4% 11.5% 16.2% 2006 2018 2022 EBITDA Margins $0.14 $2.67 $3.04 2006 2018 2022 Adjusted EPS 2022 data is pro forma for acquisition of Avient Protective Materials and Distribution divestiture TOP-TIER SUSTAINABILITY PERFORMANCE AND RECOGNITION Industry Sustainability Standards 90th percentile 87th ESG Ratings Performance 2 2 5 5 Innovation is the lifeblood of a specialty company. Global Compact • Highlights ESG Performance, including ratings, awards, and certifications • Features increased carbon emissions disclosures, including Climate Change Scenario Analysis and Scope 3 emissions data • Outlines Sustainable Supplier Program, designed to enable supplier evaluation & collaboration • Reflects Great Place To Work® culture focused on safety, employee engagement and advancing diversity, equity and inclusion 2022 SUSTAINABILITY REPORT 19 Avient Confidential 20 • Virtual presentation to be held September 20, 2023 • Leadership will be conducting an investor-focused presentation around our sustainable solutions portfolio • Deep dive into how we enable customers to achieve their sustainability goals SUSTAINABILITY DAY 20 …are Growing at Twice the Rate as Conventional Products Sustainably-Branded Products… STAKEHOLDER INFLUENCE DRIVES DEMAND Consumers Are demanding recyclability and eco- conscious products Governments Are mandating changes through legislation, taxes, and regional accords Brand Owners Have committed to ambitious goals to achieve sustainability metrics 21 AP P EN D IX 24 Performance Additives 16% Pigments 12% TiO2 10% Dyestuffs 2% Polyethylene 11% Nylon 6% Polypropylene 5% Styrenic Block Copolymer 5% Other Raw Materials 33% ~40% hydrocarbon based (Grey shaded materials are hydrocarbon based, includes portion of “Other Raw Materials”) Non-hydrocarbon based materials 2022 pro forma results for the acquisition of Avient Protective Materials RAW MATERIAL BASKET PEER COMPARISONS AVIENT IS ASSET LIGHT Capex / Revenue 2023E (%) Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of August 17, 2023 Note: Avient reflects 2023 estimated revenue of $3,280 and estimated run-rate CAPEX of $110M. 26 3 2 3 3 4 4 3 4 5 5 7 7 9 10 A vi en t K W R P P G F U L A V Y R P M F M C H U N C E E C L A S H H X L E M N S C L FREE CASH FLOW CONVERSION Source: Peer data per Bloomberg as of August 17, 2023 Note: Free cash flow conversion calculated as (Adjusted EBITDA – Capex) / Adjusted EBITDA. Avient reflects 2023 adjusted EBITDA guidance of $525M and estimated run-rate CAPEX of $110M. 2023E (%) 27 79 89 83 83 78 75 90 81 76 72 68 63 53 11 A vi en t K W R F U L P P G A V Y R P M F M C C E E C L A S H H X L H U N E M N S C L Avient Specialty Formulators Other Specialty / Chemical Companies MULTIPLE EXPANSION Source: Peer data per Bloomberg as of August 17, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $525M and closing share price of $37.07.